(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 22.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.21%.
Ardelyx's revenue in 2026 is $450,894,000.On average, 14 Wall Street analysts forecast ARDX's revenue for 2026 to be $124,232,464,021, with the lowest ARDX revenue forecast at $116,054,127,908, and the highest ARDX revenue forecast at $131,608,416,152. On average, 14 Wall Street analysts forecast ARDX's revenue for 2027 to be $158,363,685,757, with the lowest ARDX revenue forecast at $137,511,669,732, and the highest ARDX revenue forecast at $192,138,569,266.
In 2028, ARDX is forecast to generate $212,078,558,778 in revenue, with the lowest revenue forecast at $158,727,499,613 and the highest revenue forecast at $246,638,383,138.